Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9283MR)

This product GTTS-WQ9283MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9283MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14645MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ16002MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ4901MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ7262MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ15990MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ10258MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ5717MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA TCB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW